secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001104659-26-040661
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron expects ~$102M IPR&D charge in Q1 2026, ~$0.81 EPS hit
----------------------------------------------------------------

- Pre-tax acquired IPR&D charge of ~$102M from milestone/up-front payments and equity securities premium.
- Charge expected to reduce GAAP and non-GAAP diluted EPS by ~$0.81 each for Q1 2026.
- Results are preliminary, subject to closing procedures; actuals may differ.
- Regeneron does not forecast such charges due to transaction uncertainty.
- Company reiterates non-GAAP measure excludes certain items not viewed as useful.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465926040661/0001104659-26-040661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465926040661/tm2611354d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-040661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer